Bizarre how quiet this thread is the day before listing
Anyway, plenty of potential in this little bio IMO:
MC: $26m
Cash in bank: $10m
EV: $16m
Senior Leadership team own ~23% of company. CEO Michael Aldridge has been involved in numerous pharma company exits, ranging from $300M to US $5.6B, Chairman Prof. Jonathan West is a former Assoc. Prof. at Harvard Business School and an advisor to major corporates including DuPont, Roche, Novartis and Syngenta.
The company is looking to address the US $3.7bn Nail Fungal treatment market with >25 million invested in R+D of HXP124 to date. It has been shown to be twice as effective as current topical products, after only six-weeks of treatment. Peak sales for Jublia®, the existing leading topical product in the USA are >US$330m pa.
With 10 mill cash at bank upon listing, the company is well funded through their Phase IIb trials in 2021.
GLTA Holders!
- Forums
- ASX - By Stock
- IPO - Hexima Limited
Bizarre how quiet this thread is the day before listing Anyway,...
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add HXL (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.837M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 2663156 | 1.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.2¢ | 272815 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 2663156 | 0.010 |
4 | 533429 | 0.009 |
1 | 100000 | 0.008 |
1 | 130000 | 0.007 |
5 | 1583135 | 0.006 |
Price($) | Vol. | No. |
---|---|---|
0.012 | 272815 | 1 |
0.013 | 1388199 | 3 |
0.014 | 588589 | 2 |
0.015 | 631062 | 1 |
0.018 | 350000 | 1 |
Last trade - 16.12pm 03/05/2024 (20 minute delay) ? |
Featured News
HXL (ASX) Chart |
Day chart unavailable